Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T12:45:26.250Z.
Calculation as of: 2026-10-06T12:45:26.250Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c4088ee3877f0fa8fb1d478ebd945bbdf3f6f56484e99899685bc9bfb173ee48
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$4.42M
EV/EBITDA Ratio
N/A
TTM Avg
72.60x
3Y Avg
72.60x
5Y Avg
72.60x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | $3.94M | N/A | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.18M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.59M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | N/A | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.48M | N/A | N/A | N/A | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.47M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.42M | N/A | 72.60x | 72.60x | 72.60x |
| Aethlon Medical, Inc. (AEMD)vs › | $3.44M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
